IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v25y2007i12p997-1006.html
   My bibliography  Save this article

NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors

Author

Listed:
  • Denis Getsios
  • Kristen Migliaccio-Walle
  • Jaime Caro

Abstract

The National Institute for Health and Clinical Excellence (NICE) recently issued updated guidance on the use of cholinesterase inhibitors in the treatment of Alzheimer’s disease. NICE initially recommended that cholinesterase inhibitors no longer be used, but final guidance restricted treatment to patients with disease of a moderately severe stage. This decision was based largely on results from a heavily criticised economic evaluation that used an adaptation of the Assessment of Health Economics in Alzheimer’s Disease (AHEAD) model. As the developers of the AHEAD model, we examined the appropriateness of NICE’s economic analyses and presentation of results. We attempted to replicate NICE’s results by modifying the original AHEAD model. Sensitivity analyses were then run using the modified AHEAD model to evaluate the extent of uncertainty in predictions. The AHEADNICE analyses resulted in an incremental cost-effectiveness ratio for galantamine of £82 000 per QALY gained (year 2003 values) from the perspective of the UK NHS and Personal Social Services. This was later revised to £46 000 per QALY, compared with >£9000 per discounted QALY gained (year 2001 values) in the original AHEAD model. Using our modified AHEAD with effectiveness estimates matching those of AHEADNICE, we show that NICE’s choice and presentation of sensitivity analyses obscured the instability of their estimates. In the final NICE evaluation, the recommendation to delay treatment with cholinesterase inhibitors until patients have moderately severe disease was based on critical assumptions in the economic analyses that had little evidence to support them. The case of NICE’s guidance on cholinesterase inhibitors highlights the importance of transparent and valid economic evaluations and the dangers of using inappropriate modelling technologies, basing analyses on a limited subset of the available data, and insufficiently reflecting the uncertainty in estimates that are intended to inform decision makers. Copyright Adis Data Information BV 2007

Suggested Citation

  • Denis Getsios & Kristen Migliaccio-Walle & Jaime Caro, 2007. "NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors," PharmacoEconomics, Springer, vol. 25(12), pages 997-1006, December.
    • Handle: RePEc:spr:pharme:v:25:y:2007:i:12:p:997-1006
    DOI: 10.2165/00019053-200725120-00003
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200725120-00003
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/00019053-200725120-00003?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. A. E. Ades & Karl Claxton & Mark Sculpher, 2006. "Evidence synthesis, parameter correlation and probabilistic sensitivity analysis," Health Economics, John Wiley & Sons, Ltd., vol. 15(4), pages 373-381, April.
    2. Alan Brennan & Stephen E. Chick & Ruth Davies, 2006. "A taxonomy of model structures for economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 15(12), pages 1295-1310, December.
    3. Nick Bosanquet & Andrew Yeates, 2006. "Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer’s Disease," PharmacoEconomics, Springer, vol. 24(6), pages 623-625, June.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Eric Stallard & Bruce Kinosian & Arthur S. Zbrozek & Anatoliy I. Yashin & Henry A. Glick & Yaakov Stern, 2010. "Estimation and Validation of a Multiattribute Model of Alzheimer Disease Progression," Medical Decision Making, , vol. 30(6), pages 625-638, November.
    2. Dixon, Josie & Ferdinand, Monique & D'Amico, Francesco & Knapp, Martin, 2015. "Exploring the cost-effectiveness of a one-off screen for dementia (for people aged 75 years in England and Wales)," LSE Research Online Documents on Economics 58109, London School of Economics and Political Science, LSE Library.
    3. Jacques Touchon & Jean Lachaine & Catherine Beauchemin & Anna Granghaud & Benoit Rive & Sébastien Bineau, 2014. "The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(8), pages 791-800, November.
    4. Denis Getsios & Steve Blume & K. Ishak & Grant Maclaine, 2010. "Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer’s Disease," PharmacoEconomics, Springer, vol. 28(5), pages 411-427, May.
    5. Kristin Kahle-Wrobleski & Howard Fillit & Jonathan Kurlander & Catherine Reed & Mark Belger, 2015. "Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer’s disease clinical trials," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 995-1004, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Heß, Michael (Ed.) & Schlieter, Hannes (Ed.), 2014. "Modellierung im Gesundheitswesen: Tagungsband des Workshops im Rahmen der Modellierung 2014," ICB Research Reports 57, University Duisburg-Essen, Institute for Computer Science and Business Information Systems (ICB).
    2. Ortiz-Barrios, Miguel & Arias-Fonseca, Sebastián & Ishizaka, Alessio & Barbati, Maria & Avendaño-Collante, Betty & Navarro-Jiménez, Eduardo, 2023. "Artificial intelligence and discrete-event simulation for capacity management of intensive care units during the Covid-19 pandemic: A case study," Journal of Business Research, Elsevier, vol. 160(C).
    3. Bernhard Ultsch & Oliver Damm & Philippe Beutels & Joke Bilcke & Bernd Brüggenjürgen & Andreas Gerber-Grote & Wolfgang Greiner & Germaine Hanquet & Raymond Hutubessy & Mark Jit & Mirjam Knol & Rüdiger, 2016. "Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community," PharmacoEconomics, Springer, vol. 34(3), pages 227-244, March.
    4. Hossein Haji Ali Afzali & Laura Bojke & Jonathan Karnon, 2018. "Model Structuring for Economic Evaluations of New Health Technologies," PharmacoEconomics, Springer, vol. 36(11), pages 1309-1319, November.
    5. Becky Pennington & Alex Filby & Lesley Owen & Matthew Taylor, 2018. "Smoking Cessation: A Comparison of Two Model Structures," PharmacoEconomics, Springer, vol. 36(9), pages 1101-1112, September.
    6. Gemma E. Shields & Mark Wilberforce & Paul Clarkson & Tracey Farragher & Arpana Verma & Linda M. Davies, 2022. "Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency," PharmacoEconomics, Springer, vol. 40(2), pages 149-156, February.
    7. Fernando Alarid-Escudero & Richard F. MacLehose & Yadira Peralta & Karen M. Kuntz & Eva A. Enns, 2018. "Nonidentifiability in Model Calibration and Implications for Medical Decision Making," Medical Decision Making, , vol. 38(7), pages 810-821, October.
    8. Koen Degeling & Maarten J. IJzerman & Mariel S. Lavieri & Mark Strong & Hendrik Koffijberg, 2020. "Introduction to Metamodeling for Reducing Computational Burden of Advanced Analyses with Health Economic Models: A Structured Overview of Metamodeling Methods in a 6-Step Application Process," Medical Decision Making, , vol. 40(3), pages 348-363, April.
    9. Peter J. Dodd & Jeff J. Pennington & Liza Bronner Murrison & David W. Dowdy, 2018. "Simple Inclusion of Complex Diagnostic Algorithms in Infectious Disease Models for Economic Evaluation," Medical Decision Making, , vol. 38(8), pages 930-941, November.
    10. Jonathan Karnon & James Stahl & Alan Brennan & J. Jaime Caro & Javier Mar & Jörgen Möller, 2012. "Modeling Using Discrete Event Simulation," Medical Decision Making, , vol. 32(5), pages 701-711, September.
    11. Annika Hoyer & Sophie Kaufmann & Ralph Brinks, 2019. "Risk factors in the illness-death model: Simulation study and the partial differential equation about incidence and prevalence," PLOS ONE, Public Library of Science, vol. 14(12), pages 1-10, December.
    12. Olivier Ethgen & Baudouin Standaert, 2012. "Population–versus Cohort–Based Modelling Approaches," PharmacoEconomics, Springer, vol. 30(3), pages 171-181, March.
    13. Stuart J. Wright & William G. Newman & Katherine Payne, 2019. "Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review," PharmacoEconomics, Springer, vol. 37(8), pages 1011-1027, August.
    14. Arielle Anderer & Hamsa Bastani & John Silberholz, 2022. "Adaptive Clinical Trial Designs with Surrogates: When Should We Bother?," Management Science, INFORMS, vol. 68(3), pages 1982-2002, March.
    15. Mehdi Javanbakht & Jesse Fishman & Eoin Moloney & Peter Rydqvist & Amir Ansaripour, 2023. "Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis," PharmacoEconomics - Open, Springer, vol. 7(1), pages 93-110, January.
    16. Eren Demir & David Southern, 2017. "Enabling better management of patients: discrete event simulation combined with the STAR approach," Journal of the Operational Research Society, Palgrave Macmillan;The OR Society, vol. 68(5), pages 577-590, May.
    17. Jen Kruger & Daniel Pollard & Hasan Basarir & Praveen Thokala & Debbie Cooke & Marie Clark & Rod Bond & Simon Heller & Alan Brennan, 2015. "Incorporating Psychological Predictors of Treatment Response into Health Economic Simulation Models," Medical Decision Making, , vol. 35(7), pages 872-887, October.
    18. Oakley, Jeremy E. & Brennan, Alan & Tappenden, Paul & Chilcott, Jim, 2010. "Simulation sample sizes for Monte Carlo partial EVPI calculations," Journal of Health Economics, Elsevier, vol. 29(3), pages 468-477, May.
    19. Eline M. Krijkamp & Fernando Alarid-Escudero & Eva A. Enns & Hawre J. Jalal & M. G. Myriam Hunink & Petros Pechlivanoglou, 2018. "Microsimulation Modeling for Health Decision Sciences Using R: A Tutorial," Medical Decision Making, , vol. 38(3), pages 400-422, April.
    20. Sarah Bates & Thomas Bayley & Paul Norman & Penny Breeze & Alan Brennan, 2020. "A Systematic Review of Methods to Predict Weight Trajectories in Health Economic Models of Behavioral Weight-Management Programs: The Potential Role of Psychosocial Factors," Medical Decision Making, , vol. 40(1), pages 90-105, January.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:25:y:2007:i:12:p:997-1006. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.